Jefferies Financial Group Upgrades Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) to Strong-Buy

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was upgraded by analysts at Jefferies Financial Group from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other research analysts have also recently weighed in on the company. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 2.6%

OTCMKTS:SGIOY opened at $8.70 on Tuesday. Shionogi & Co., Ltd. Unsponsored ADR has a one year low of $7.65 and a one year high of $12.00. The business has a fifty day moving average price of $8.99 and a 200-day moving average price of $9.90. The firm has a market capitalization of $14.81 billion, a price-to-earnings ratio of 10.88, a price-to-earnings-growth ratio of 3.47 and a beta of 0.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%.The company had revenue of $881.71 million for the quarter, compared to the consensus estimate of $895.52 million. Sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.